Detection of Biomarkers to Predict and Monitor Response to Infliximab
M
Marian Pfefferkorn
Primary Investigator
Enrolling By Invitation
3-20 years
All
Phase
N/A
25 participants needed
2 Locations
Brief description of study
The purpose of this study is to learn more about biomarkers in the blood that will help predict and monitor response to infliximab.
Detailed description of study
This study will take 54 weeks to complete, during which time researchers will meet with participants during the infliximab infusions used to help treat their inflammatory bowel disease.
During the first visit, researchers will disucss medical history and medications with participants, measure height and weight and examine the belly, collect a stool sample, and take an additional 2-3 tubes of blood during the needed blood draw for infusion.
During the three additional study visits (during infusion 4, 6, and 9), researchers will disucss changes in medications and symptoms with participants, measure height and weight and examine the belly, collect a stool sample, and take an additional 2-3 tubes of blood during the needed blood draw for infusion.
Participants will receive a $10 gift card for each completed study visit.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Inflammatory Bowel, IBS, Crohn's Disease, Riley
-
Age: Between 3 Years - 20 Years
-
Gender: All
Individuals between 3 and 20 years of age who will be starting infliximab for treatment of Crohn's disease.
Individuals who have already undergone significant bowel surgery will not be eligible.
Updated on
13 Sep 2024.
Study ID: 1911802085, PGI-MGH-SOMASCAN
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
